Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Timing Is Everything – Unfortunately For Acorda, Timing Couldn't Be Worse

Executive Summary

Acorda can't seem to catch a break. The Federal Circuit slapped down the company's last ditch effort to uphold its Ampyra patents and three days later the FDA postponed a decision on Inbrija, widening the gap between the entry of Ampyra generics and the launch of Acorda's new drug.

Advertisement

Related Content

Keeping Track: AstraZeneca Wins Approval For Lumoxiti, AbbVie Expands Label For Venclexta With MRD Data, and FDA Delays Acorda's Inbrijia NDA
Combo-Product Sponsors Could More Easily Get Device Designation At US FDA
Acorda Decides Tozadenant Isn’t Salvageable, Moves Primary Focus To Inbrija
Finance Watch: Second Quarter Begins With Solid Base For Biopharma VC, Shaky Ground For Acorda
Deep Breath For Acorda As It Prepares Inhaled Levodopa Filing

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123836

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel